Enhancing The NIH’s Return On Investment For Taxpayers
The National Institutes of Health (NIH) could improve its return on investment for taxpayers by promoting transparency, competition, and institutional accountability. The NIH's current funding system has been criticized for incentivizing incrementalism and lacking rigorous mechanisms to evaluate the outcomes of publicly funded research.
The National Institutes of Health (NIH) has been at the center of US biomedical research for over half a century, with an annual budget exceeding $45 billion. The NIH's investments shape the trajectory of the life sciences and influence innovation across academia, biotechnology, and the pharmaceutical industry. Concerns have been raised that the current system incentivizes incrementalism and lacks mechanisms to evaluate whether public dollars produce meaningful outcomes. To address this, the NIH should define and publish spending data for basic, clinical, and translational research. A more decentralized approach to funding basic research should be considered, as it has been shown to excel on innovation outcomes and encourage participation from younger and smaller firms. The NIH funding process determines much of the academic science conducted in the United States, and applications are evaluated using the NIH's scoring criteria.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.